论文部分内容阅读
目的:观察氨溴特罗口服液辅助治疗婴幼儿支气管肺炎的疗效。方法:76例婴幼儿支气管肺炎患儿随机分为两组,治疗组口服氨溴特罗口服液、对照组口服急支糖浆。观察两组咳嗽、咯痰、喘息、发热、鼻塞、流涕、咽部充血及肺部啰音消失等综合症状改善情况,比较两组C反应蛋白(CRP)恢复情况以及临床总有效率。结果:治疗组综合疗效改善率明显优于对照组,CRP恢复率明显高于对照组(P<0.05);治疗组总有效率为92.1%,对照组为73.0%,两组比较差异有统计学意义(P<0.05)。结论:氨溴特罗口服液可以快速改善支气管肺炎患儿的临床症状,可以作为婴幼儿支气管肺炎的临床辅助用药。
Objective: To observe the efficacy of ambroxol oral solution in the treatment of infantile bronchopneumonia. Methods: A total of 76 infants with bronchial pneumonia were randomly divided into two groups. The treatment group was treated with oral ambroxol solution and the control group with oral acute oral syrup. The improvement of the symptoms such as cough, expectoration, wheezing, fever, nasal congestion, runny nose, throat congestion and disappearance of pulmonary rales were observed in two groups. The recovery of C-reactive protein (CRP) and total effective rate were compared between the two groups. Results: The improvement rate of comprehensive curative effect in treatment group was significantly better than that in control group, and the recovery rate of CRP was significantly higher than that in control group (P <0.05). The total effective rate was 92.1% in treatment group and 73.0% in control group, with statistically significant difference Significance (P <0.05). Conclusion: Ambroxol oral solution can rapidly improve the clinical symptoms of children with bronchopneumonia and can be used as a clinical adjuvant for bronchial pneumonia in infants.